ES2509959T3 - Métodos y composiciones - Google Patents
Métodos y composiciones Download PDFInfo
- Publication number
- ES2509959T3 ES2509959T3 ES12151953.2T ES12151953T ES2509959T3 ES 2509959 T3 ES2509959 T3 ES 2509959T3 ES 12151953 T ES12151953 T ES 12151953T ES 2509959 T3 ES2509959 T3 ES 2509959T3
- Authority
- ES
- Spain
- Prior art keywords
- exposure
- polypeptide
- peptides
- nucleic acid
- bound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title description 3
- 239000000203 mixture Substances 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract description 26
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 18
- 229920001184 polypeptide Polymers 0.000 abstract 5
- 108020004707 nucleic acids Proteins 0.000 abstract 3
- 102000039446 nucleic acids Human genes 0.000 abstract 3
- 150000007523 nucleic acids Chemical class 0.000 abstract 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 abstract 1
- 230000001580 bacterial effect Effects 0.000 abstract 1
- 150000001875 compounds Chemical group 0.000 abstract 1
- -1 linker compound Chemical class 0.000 abstract 1
- 108020004999 messenger RNA Proteins 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 description 7
- 230000003115 biocidal effect Effects 0.000 description 6
- 125000003367 polycyclic group Chemical group 0.000 description 5
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 4
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 4
- 125000000151 cysteine group Chemical class N[C@@H](CS)C(=O)* 0.000 description 4
- 101001091365 Homo sapiens Plasma kallikrein Proteins 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 235000018417 cysteine Nutrition 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 2
- 102100038358 Prostate-specific antigen Human genes 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 2
- 230000000843 anti-fungal effect Effects 0.000 description 2
- 230000000118 anti-neoplastic effect Effects 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 239000000562 conjugate Substances 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229960003444 immunosuppressant agent Drugs 0.000 description 2
- 230000001861 immunosuppressant effect Effects 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 239000000863 peptide conjugate Substances 0.000 description 2
- 230000003252 repetitive effect Effects 0.000 description 2
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
- 102400000345 Angiotensin-2 Human genes 0.000 description 1
- 101800000733 Angiotensin-2 Proteins 0.000 description 1
- 101001107784 Caenorhabditis elegans Deoxyribonuclease-2 Proteins 0.000 description 1
- 108010020326 Caspofungin Proteins 0.000 description 1
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- 108010013198 Daptomycin Proteins 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 108090000204 Dipeptidase 1 Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 101150029707 ERBB2 gene Proteins 0.000 description 1
- 108010080805 Factor XIa Proteins 0.000 description 1
- 206010019860 Hereditary angioedema Diseases 0.000 description 1
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 1
- 102000001399 Kallikrein Human genes 0.000 description 1
- 108060005987 Kallikrein Proteins 0.000 description 1
- 229940127379 Kallikrein Inhibitors Drugs 0.000 description 1
- 101001091363 Mus musculus Plasma kallikrein Proteins 0.000 description 1
- 102400000050 Oxytocin Human genes 0.000 description 1
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 1
- 101800000989 Oxytocin Proteins 0.000 description 1
- 102000019280 Pancreatic lipases Human genes 0.000 description 1
- 108050006759 Pancreatic lipases Proteins 0.000 description 1
- 108010067902 Peptide Library Proteins 0.000 description 1
- 108010093965 Polymyxin B Proteins 0.000 description 1
- PZBFGYYEXUXCOF-UHFFFAOYSA-N TCEP Chemical compound OC(=O)CCP(CCC(O)=O)CCC(O)=O PZBFGYYEXUXCOF-UHFFFAOYSA-N 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- ZWBTYMGEBZUQTK-PVLSIAFMSA-N [(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,32-tetrahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-1'-(2-methylpropyl)-6,23-dioxospiro[8,33-dioxa-24,27,29-triazapentacyclo[23.6.1.14,7.05,31.026,30]tritriaconta-1(32),2,4,9,19,21,24,26,30-nonaene-28,4'-piperidine]-13-yl] acetate Chemical compound CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c4NC5(CCN(CC(C)C)CC5)N=c4c(=NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C ZWBTYMGEBZUQTK-PVLSIAFMSA-N 0.000 description 1
- GJEAMHAFPYZYDE-UHFFFAOYSA-N [C].[S] Chemical compound [C].[S] GJEAMHAFPYZYDE-UHFFFAOYSA-N 0.000 description 1
- 229930183665 actinomycin Natural products 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229960003942 amphotericin b Drugs 0.000 description 1
- 229960004099 azithromycin Drugs 0.000 description 1
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 1
- 102000006635 beta-lactamase Human genes 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- JYIKNQVWKBUSNH-WVDDFWQHSA-N caspofungin Chemical compound C1([C@H](O)[C@@H](O)[C@H]2C(=O)N[C@H](C(=O)N3CC[C@H](O)[C@H]3C(=O)N[C@H](NCCN)[C@H](O)C[C@@H](C(N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N2)[C@@H](C)O)=O)NC(=O)CCCCCCCC[C@@H](C)C[C@@H](C)CC)[C@H](O)CCN)=CC=C(O)C=C1 JYIKNQVWKBUSNH-WVDDFWQHSA-N 0.000 description 1
- 229960003034 caspofungin Drugs 0.000 description 1
- 238000003889 chemical engineering Methods 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- DOAKLVKFURWEDJ-QCMAZARJSA-N daptomycin Chemical compound C([C@H]1C(=O)O[C@H](C)[C@@H](C(NCC(=O)N[C@@H](CCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@H](CO)C(=O)N[C@H](C(=O)N1)[C@H](C)CC(O)=O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](CC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CCCCCCCCC)C(=O)C1=CC=CC=C1N DOAKLVKFURWEDJ-QCMAZARJSA-N 0.000 description 1
- 229960005484 daptomycin Drugs 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- FABUFPQFXZVHFB-CFWQTKTJSA-N ixabepilone Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@H](C)C(=O)C(C)(C)[C@H](O)CC(=O)N1)O)C)=C\C1=CSC(C)=N1 FABUFPQFXZVHFB-CFWQTKTJSA-N 0.000 description 1
- 229960002014 ixabepilone Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 125000001827 mesitylenyl group Chemical group [H]C1=C(C(*)=C(C([H])=C1C([H])([H])[H])C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 1
- 229960001723 oxytocin Drugs 0.000 description 1
- 229940116369 pancreatic lipase Drugs 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920000024 polymyxin B Polymers 0.000 description 1
- 229960005266 polymyxin b Drugs 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 229960000885 rifabutin Drugs 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 229960003165 vancomycin Drugs 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1062—Isolating an individual clone by screening libraries mRNA-Display, e.g. polypeptide and encoding template are connected covalently
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
- C07K1/1075—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of amino acids or peptide residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
- C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1041—Ribosome/Polysome display, e.g. SPERT, ARM
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1068—Template (nucleic acid) mediated chemical library synthesis, e.g. chemical and enzymatical DNA-templated organic molecule synthesis, libraries prepared by non ribosomal polypeptide synthesis [NRPS], DNA/RNA-polymerase mediated polypeptide synthesis
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/04—Libraries containing only organic compounds
- C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
- C40B40/08—Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B50/00—Methods of creating libraries, e.g. combinatorial synthesis
- C40B50/06—Biochemical methods, e.g. using enzymes or whole viable microorganisms
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/04—Libraries containing only organic compounds
- C40B40/10—Libraries containing peptides or polypeptides, or derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Crystallography & Structural Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Food Science & Technology (AREA)
Abstract
Colección de polipéptidos codificados genéticamente de complejos que comprenden un ácido nucleico que codifica un polipéptido, en donde: (i) el polipéptido codificado por el ácido nucleico está unido al ácido nucleico; (ii) un compuesto conector unido a dicho polipéptido; (iii) el compuesto conector está unido al polipéptido mediante al menos tres enlaces covalentes independientes; y (iv) la colección es una genoteca exposición de ARNm, exposición de ADN, exposición en levadura, exposición en ribosomas o exposición en bacterias.
Description
E12151953
02-10-2014
calicreína plasmática humana (<2000 Da). Nuestro mejor inhibidor (PK15) con Ki = 1,5 nM interrumpe con eficacia la vía de la coagulación intrínseca en el plasma humano analizado ex vivo, y era muy específico: no inhibía la calicreína plasmática de ratón ni las proteasas plasmáticas homólogas humanas factor XIa y trombina.
Nuestro repertorio se construyó a partir de péptidos de 17 restos con tres cisteínas, separadas entre sí por seis
5 aminoácidos aleatorios. Después de la conjugación con TBMB, se espera que los péptidos formen dos lazos de seis restos unidos a un núcleo de mesitileno, como se confirmó realmente gracias a la estructura del inhibidor de la calicreína PK15 resuelto por RMN (figura 14). Tales péptidos policíclicos deben tener ventajas tanto sobre los péptidos con puentes disulfuro como con los lineales. Las ventajas de los péptidos policíclicos sobre los péptidos con puentes disulfuro son que los enlaces covalentes azufre-carbono, una vez que se forman, son inertes para el
10 intercambio18, y también son estables en un entorno reductor18. La ventaja de los péptidos policíclicos sobre los péptidos lineales es que están interconectados y más constreñidos. Esto tiene dos consecuencias principales: (a) los péptidos constreñidos se espera que se unan más estrechamente a las dianas (debido a la menor pérdida de entropía conformacional). Nuestra revisión de la bibliografía sobre inhibidores peptídicos que se han aislado por exposición en fagos muestra que la mayoría contienen puentes disulfuro y tienen constantes de inhibición del orden
15 micromolar (tabla 3).
Tabla 3: Inhibidores peptídicos seleccionados en fagos. Se indican la secuencia de los péptidos, la diana de la enzima y la afinidad de unión. Los restos de cisteína que forman puentes disulfuro están subrayados.
- Diana
- Secuencia peptídica Afinidad Referencia
- Antígeno prostático específico (PSA)
-
imagen36 KD = 2,9 µM 1
- Calicreína 2 humana
-
imagen37 CI50 = 3,4 µM 2
- Activador del plasminógeno de tipo urocinasa (uPA)
-
imagen38 Ki = 6,7 µM 3
- Activador del plasminógeno de tipo urocinasa (uPA)
-
imagen39 Ki = 0,4 µM 4
- Quimotripsina
-
imagen40 Ki = 1 µM 5
- TF-fVII
-
imagen41 CI50 = 1,5 nM 6
- Enzima convertidora de la angiotensina 2 (ACE2)
-
imagen42 KI = 2,8 nM 7
- ErbB-2
-
imagen43 Ki = 30 µM 8
- Ureasa
-
imagen44 CI50 = 30 µM 9
- Lipasa pancreática
-
imagen45 CI50 = 16 µM 10
- β-Lactamasa
-
imagen46 CI50 = 9 µM 11
- DNasa II
-
imagen47 KI = 0,2 µM 12
Sólo dos inhibidores peptídicos fueron tan potentes como la PK15; ambos contenían un puente disulfuro y al menos
20 dos restos de triptófano19-20 . Esto sugiere que (a) la conformación constreñida y la posibilidad de formar interacciones hidrófobas son clave para estas afinidades elevadas; (b) los péptidos constreñidos (e interconectados) también deben ser más resistentes a la escisión y/o inactivación que los péptidos lineales. De hecho, en nuestro trabajo se escindió uno de los lazos del inhibidor PK15 después de la incubación prolongada con la calicreína plasmática humana, pero permaneció intacta y activa.
25 Los conjugados policíclicos se prestan a la ingeniería genética y química. La masa molecular del PK15 (1939,4 Da) es mayor que la de varios fármacos macrocíclicos peptídicos (tabla 2), pero sería posible utilizar lazos más pequeños. Por ejemplo, al alterar el espaciado de las cisteínas, se varía directamente la longitud del lazo, o incluso 37
E12151953
02-10-2014
se añaden segmentos adicionales a los extremos de los péptidos. Tabla 2. Comparación de tamaños de los fármacos macrocíclicos.
- Nombre
- Tamaño del ciclo o de los ciclos Masa molecular (Da) Aplicación
- Actinomicina
- 16,16 1255,42 Antineoplásico
- Amfotericina B
- 38 924,08 Antimicótico
- Azitromicina
- 15 748,88 Antibiótico
- Caspofungina
- 21 1093,31 Antimicótico
- Ciclosporina
- 32 1202,61 Inmunodepresor
- Daptomicina
- 31 1619,71 Antibiótico
- Eritromicina
- 14 733,93 Antibiótico
- Ixabepilona
- 16 506,70 Antineoplásico
- Ocreótido
- 20 1019,24 Hormona
- Oxitocina
- 20 1007,19 Hormona
- Polimixina B
- 23 1301,56 Antibiótico
- Rapamicina
- 29 914,17 Inmunodepresor
- Rifabutina
- 27 847,01 Antibiótico
- Vancomicina
- 16, 16, 12 1449,30 Antibiótico
Otras variaciones podrían incluir la mutagénesis de los lazos (como con la maduración de la afinidad de PK15); la
5 escisión proteolítica de uno o ambos lazos para generar segmentos peptídicos «ramificados» en las cisteínas; conjugación química en los extremos del péptido naciente después de la escisión de lazo21; o el uso de variaciones en los núcleos orgánicos. Por ejemplo, un núcleo orgánico más grande, o uno con más grupos funcionales podría interaccionar más extensivamente con los lazos o con la diana, y también se podrían utilizar para introducir funciones completamente nuevas, tales como la fluorescencia. Si se realizasen estas operaciones sobre el
10 conjugado expuesto en fagos, se podrían seleccionar las variaciones mediante un proceso reiterativo. Dado que los conjugados peptídicos también son adecuados para la síntesis química, se podrían introducir sintéticamente más variaciones (tales como la sustitución mediante aminoácidos no naturales).
Los inhibidores de la calicreína plasmática humana se han desarrollado clínicamente para el tratamiento del angioedema hereditario y para la intervención quirúrgica para la derivación coronaria, pero se ha demostrado que es
15 difícil fabricar moléculas pequeñas que sean específicas de la calicreína (revisado en22,23). El hecho de que nosotros obtengamos fácilmente un inhibidor muy específico y de gran afinidad mediante la selección reiterativa de conjugados peptídicos policíclicos sobre los fagos indica que esta estrategia está bien encaminada.
Materiales y métodos
Modificación química con TBMB de los repertorios peptídicos sobre los fagos
20 Las genotecas de péptidos en fagos que se basan en el plásmido fdg3p0ss2116 se clonaron y se produjeron como se describe más adelante. Típicamente, los fagos purificados con PEG a 1011-1012 u.t. se redujeron en 20 ml de NH4HCO3 a 20 mM, pH 8 con TCEP a 1 mM a 42 ºC durante 1 hora. Los fagos se centrifugaron a 4000 rpm en un filtro Vivaspin 20 (masa molecular límite de 10 000) para reducir el volumen del tampón de reducción a 1 ml y se lavó dos veces con 10 ml de tampón de reacción enfriado en hielo (NH4HCO3 a 20 mM y EDTA a 5 mM, pH 8). El
38
Claims (1)
-
imagen1 imagen2
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0802079.4A GB0802079D0 (en) | 2008-02-05 | 2008-02-05 | Method and compositions |
GB0802079 | 2008-02-05 | ||
GB0818399 | 2008-10-08 | ||
GB0818399A GB0818399D0 (en) | 2008-10-08 | 2008-10-08 | Methods and compositions |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2509959T3 true ES2509959T3 (es) | 2014-10-20 |
Family
ID=40792924
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES12151953.2T Active ES2509959T3 (es) | 2008-02-05 | 2009-02-04 | Métodos y composiciones |
ES09708496T Active ES2383191T3 (es) | 2008-02-05 | 2009-02-04 | Métodos y composiciones |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES09708496T Active ES2383191T3 (es) | 2008-02-05 | 2009-02-04 | Métodos y composiciones |
Country Status (11)
Country | Link |
---|---|
US (3) | US8680022B2 (es) |
EP (5) | EP2653545A1 (es) |
JP (2) | JP6074574B2 (es) |
AT (1) | ATE555200T1 (es) |
AU (1) | AU2009211253B2 (es) |
CA (1) | CA2714477C (es) |
DK (2) | DK2474613T3 (es) |
ES (2) | ES2509959T3 (es) |
PL (1) | PL2257624T3 (es) |
PT (1) | PT2257624E (es) |
WO (1) | WO2009098450A2 (es) |
Families Citing this family (139)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0913775D0 (en) * | 2009-08-06 | 2009-09-16 | Medical Res Council | Multispecific peptides |
GB0914110D0 (en) * | 2009-08-12 | 2009-09-16 | Medical Res Council | Peptide libraries |
JP2013518807A (ja) * | 2010-02-04 | 2013-05-23 | メディカル リサーチ カウンシル | 多重特異性ペプチド |
JP2013518558A (ja) * | 2010-02-04 | 2013-05-23 | メディカル リサーチ カウンシル | 構造化されたペプチドプロセシング |
GB201012410D0 (en) | 2010-07-23 | 2010-09-08 | Medical Res Council | Intracellular immunity |
JP6092104B2 (ja) * | 2010-08-13 | 2017-03-08 | ミティ・バイオシステムズ・ゲーエムベーハー | 修飾ペプチドディスプレイ |
GB201013980D0 (en) | 2010-08-20 | 2010-10-06 | Ecole Polytech | Bicyclic uPA inhibitors |
EP2726101B1 (en) | 2011-06-30 | 2018-08-08 | Genzyme Corporation | Inhibitors of t-cell activation |
LT3299377T (lt) * | 2011-10-07 | 2021-03-25 | Bicyclerd Limited | Struktūrizuoto polipeptido specifiškumo moduliavimas |
GB201117428D0 (en) | 2011-10-07 | 2011-11-23 | Bicycle Therapeutics Ltd | Structured polypeptides with sarcosine linkers |
US9958437B2 (en) | 2012-02-03 | 2018-05-01 | The Governors Of The University Of Alberta | Method of quantifying peptide-derivative libraries using phage display |
GB201202268D0 (en) | 2012-02-09 | 2012-03-28 | Medical Res Council | Intracellular immunity |
KR102122618B1 (ko) | 2012-05-10 | 2020-06-29 | 메사츄세츠 인스티튜트 어브 테크놀로지 | 인플루엔자 중화를 위한 작용제 |
BR112015002605B1 (pt) | 2012-08-07 | 2023-03-07 | Massachusetts Institute Of Technology | Agente de anticorpo específico para o vírus da dengue, seu uso, kit, composição farmacêutica e método para sua produção |
DK3456734T3 (da) | 2012-10-04 | 2022-04-19 | Res Found Dev | Serinproteasemolekyler og behandlinger |
MX2015006868A (es) * | 2012-11-30 | 2015-10-05 | Novartis Ag | Metodos para la elaboracion de conjugados a partir de proteinas que contienen disulfuro. |
GB201306623D0 (en) * | 2013-04-11 | 2013-05-29 | Bicycle Therapeutics Ltd | Modulation of structured polypeptide specificity |
US9868767B2 (en) | 2013-05-23 | 2018-01-16 | Ohio State Innovation Foundation | Chemical synthesis and screening of bicyclic peptide libraries |
WO2014197723A2 (en) | 2013-06-05 | 2014-12-11 | Massachusetts Institute Of Technology | Human adaptation of h7 ha |
JP6474404B2 (ja) | 2013-08-14 | 2019-02-27 | ウィリアム マーシュ ライス ユニバーシティWilliam Marsh Rice University | ウンシアラマイシン誘導体、合成方法、および抗腫瘍薬としてのそれらの使用 |
WO2015063465A2 (en) | 2013-10-28 | 2015-05-07 | Bicycle Therapeutics Limited | Novel polypeptides |
CA2938495A1 (en) | 2014-02-11 | 2015-08-20 | Massachusetts Institute Of Technology | Full spectrum anti-dengue antibody |
EP3137482A1 (en) | 2014-05-02 | 2017-03-08 | MorphoSys AG | Peptide libraries |
GB201413086D0 (en) | 2014-07-23 | 2014-09-03 | Imp Innovations Ltd And Inst Pasteur | Methods |
AU2015336857B2 (en) | 2014-10-22 | 2020-04-09 | The Governors Of The University Of Alberta | Genetic encoding of chemical post-translational modification for phage-displayed libraries |
JP6882978B2 (ja) | 2014-10-29 | 2021-06-02 | バイスクルアールディー・リミテッド | Mt1−mmpに特異的な二環性ペプチドリガンド |
KR101693665B1 (ko) * | 2014-11-13 | 2017-01-06 | 목포해양대학교 산학협력단 | 설치와 철거가 용이한 구조를 가지는 기초의 세굴방지장치 및 이를 이용한 기초의 세굴방지방법 |
MA41022A (fr) | 2014-11-24 | 2017-10-03 | Shire Human Genetic Therapies | Ciblage lysosomial et utilisations correspondantes |
JP6609099B2 (ja) | 2014-12-10 | 2019-11-20 | キヤノン株式会社 | 放射線検出装置、及び放射線検出シート |
DK3237614T3 (da) | 2014-12-22 | 2019-09-09 | Lanthiopep Bv | Nye fremgangsmåder til fremvisning af cyklisk peptider på overfladen af bakteriofagpartikler |
ES2743448T3 (es) * | 2015-04-23 | 2020-02-19 | Hoffmann La Roche | Procedimiento y composición del polipéptido de andamio de anticuerpo de vaca |
JP2015214568A (ja) * | 2015-07-13 | 2015-12-03 | バイスクル・セラピューティクス・リミテッド | 多重特異性ペプチド |
CA3014921A1 (en) | 2016-02-16 | 2017-08-24 | Research Development Foundation | Sortase-modified molecules and uses thereof |
GB201607827D0 (en) | 2016-05-04 | 2016-06-15 | Bicycle Therapeutics Ltd | Bicyclic peptide-toxin conjugates specific for MT1-MMP |
WO2017213158A1 (ja) * | 2016-06-07 | 2017-12-14 | 株式会社カネカ | リボソームディスプレイ複合体およびその製造方法 |
TWI781963B (zh) | 2016-11-09 | 2022-11-01 | 俄亥俄州立創新基金會 | 含二硫化物細胞穿透肽及其製造與使用方法 |
US10913773B2 (en) | 2016-11-22 | 2021-02-09 | Ohio State Innovation Foundation | Bicyclic peptidyl inhibitor of tumor necrosis factor-alpha |
US11352394B2 (en) | 2016-11-22 | 2022-06-07 | Ohio State Innovation Foundation | Cyclic cell penetrating peptides comprising beta-hairpin motifs and methods of making and using thereof |
WO2018096365A1 (en) | 2016-11-27 | 2018-05-31 | Bicyclerd Limited | Methods for treating cancer |
AU2017371472A1 (en) | 2016-12-06 | 2019-06-27 | Stichting Voor De Technische Wetenschappen | Multicyclic peptides and methods for their preparation |
CN110506049A (zh) * | 2016-12-23 | 2019-11-26 | 拜斯科技术开发有限公司 | 用于结合mt1-mmp的肽配体 |
US11730819B2 (en) | 2016-12-23 | 2023-08-22 | Bicycletx Limited | Peptide derivatives having novel linkage structures |
WO2018127699A1 (en) | 2017-01-06 | 2018-07-12 | Bicyclerd Limited | Compounds for treating cancer |
GB201706477D0 (en) | 2017-04-24 | 2017-06-07 | Bicycle Therapeutics Ltd | Modification of polypeptides |
WO2018197893A1 (en) | 2017-04-27 | 2018-11-01 | Bicycletx Limited | Bicyclic peptide ligands and uses thereof |
CA3064512A1 (en) | 2017-06-09 | 2018-12-13 | Vib Vzw | Glutamine dehydrogenase inhibitors for use in muscle regeneration |
JP7301757B2 (ja) * | 2017-06-26 | 2023-07-03 | バイスクルアールディー・リミテッド | 検出可能部分を持つ二環式ペプチドリガンドおよびその使用 |
WO2019016123A1 (en) | 2017-07-17 | 2019-01-24 | Vib Vzw | TARGETING SYNAPTOGYRIN-3 IN THE TREATMENT OF TAUOPATHY |
JP2020529427A (ja) * | 2017-08-04 | 2020-10-08 | バイスクルテクス・リミテッド | Cd137に対して特異的な二環式ペプチドリガンド |
US20200291096A1 (en) | 2017-08-14 | 2020-09-17 | Bicyclerd Limited | Bicyclic peptide ligand sting conjugates and uses thereof |
US20200283482A1 (en) | 2017-08-14 | 2020-09-10 | Bicyclerd Limited | Bicyclic peptide ligand prr-a conjugates and uses thereof |
WO2019081714A1 (en) | 2017-10-26 | 2019-05-02 | Vib Vzw | POSITIVE MACROPHAGES TO PODOPLANIN |
TWI825046B (zh) | 2017-12-19 | 2023-12-11 | 英商拜西可泰克斯有限公司 | Epha2特用之雙環胜肽配位基 |
GB201721265D0 (en) | 2017-12-19 | 2018-01-31 | Bicyclerd Ltd | Bicyclic peptide ligands specific for EphA2 |
WO2019158579A1 (en) | 2018-02-13 | 2019-08-22 | Vib Vzw | Targeting minimal residual disease in cancer with rxr antagonists |
CN111902429A (zh) | 2018-02-23 | 2020-11-06 | 拜斯科技术开发有限公司 | 多聚体双环肽配体 |
AU2019247795A1 (en) | 2018-04-04 | 2020-11-12 | Bicycletx Limited | Heterotandem bicyclic peptide complexes |
US11987647B2 (en) | 2018-05-09 | 2024-05-21 | Ohio State Innovation Foundation | Cyclic cell-penetrating peptides with one or more hydrophobic residues |
GB201808835D0 (en) | 2018-05-30 | 2018-07-11 | Bicyclerd Ltd | Ligands and methods of selecting binding targets for such |
GB201810325D0 (en) * | 2018-06-22 | 2018-08-08 | Bicycletx Ltd | Peptide ligands for binding to PSMA |
GB201810327D0 (en) * | 2018-06-22 | 2018-08-08 | Bicycletx Ltd | Peptide ligands for binding to IL-17 |
GB201810320D0 (en) * | 2018-06-22 | 2018-08-08 | Bicycletx Ltd | Peptide ligands for binding to CD38 |
GB201810316D0 (en) | 2018-06-22 | 2018-08-08 | Bicyclerd Ltd | Peptide ligands for binding to EphA2 |
US11180531B2 (en) | 2018-06-22 | 2021-11-23 | Bicycletx Limited | Bicyclic peptide ligands specific for Nectin-4 |
GB201810329D0 (en) * | 2018-06-22 | 2018-08-08 | Bicycletx Ltd | Peptide ligands for binding to integrin avB3 |
JP2021531295A (ja) * | 2018-07-23 | 2021-11-18 | ザ・ガバナーズ・オブ・ザ・ユニバーシティー・オブ・アルバータ | 遺伝的にコードされた二環式ペプチドライブラリー |
US11655468B2 (en) | 2018-07-25 | 2023-05-23 | The Trustees Of Boston College | Methods and compositions of chemically modified phage libraries |
WO2020023620A1 (en) * | 2018-07-25 | 2020-01-30 | Trustees Of Boston College | Methods and compositions of chemically modified phage libraries |
JP2022512779A (ja) | 2018-10-23 | 2022-02-07 | バイスクルテクス・リミテッド | 二環式ペプチドリガンドおよびその使用 |
GB201819659D0 (en) | 2018-12-03 | 2019-01-16 | Vib Vzw | Cancer regression by inducing a regeneration-like reponse |
GB201820325D0 (en) | 2018-12-13 | 2019-01-30 | Bicyclerd Ltd | Bicyclic peptide ligands specific for psma |
SG11202106081YA (en) | 2018-12-13 | 2021-07-29 | Bicycletx Ltd | Bicyclic peptide ligands specific for mt1-mmp |
GB201820316D0 (en) | 2018-12-13 | 2019-01-30 | Bicyclerd Ltd | Bicyclic peptide ligands specific for IL-17 |
GB201820295D0 (en) | 2018-12-13 | 2019-01-30 | Bicyclerd Ltd | Bicyclic peptide ligands specific for MT1-MMP |
GB201820320D0 (en) | 2018-12-13 | 2019-01-30 | Bicyclerd Ltd | Bicyclic peptide ligands specific for FAPalpha |
GB201820288D0 (en) | 2018-12-13 | 2019-01-30 | Bicycle Tx Ltd | Bicycle peptide ligaands specific for MT1-MMP |
US20220088207A1 (en) | 2018-12-21 | 2022-03-24 | Bicycletx Limited | Bicyclic peptide ligands specific for pd-l1 |
JP2022514618A (ja) * | 2018-12-21 | 2022-02-14 | バイスクルテクス・リミテッド | Pd-l1に特異的な二環式ペプチドリガンド |
GB201900527D0 (en) | 2019-01-15 | 2019-03-06 | Bicycletx Ltd | Bicyclic peptide ligands specific for integrin avb3 |
GB201900529D0 (en) * | 2019-01-15 | 2019-03-06 | Bicycletx Ltd | Bicyclic peptide ligands specific for CD38 |
GB201900528D0 (en) | 2019-01-15 | 2019-03-06 | Bicyclerd Ltd | Bicyclic peptide ligands specific for integrin AVB3 |
GB201900526D0 (en) | 2019-01-15 | 2019-03-06 | Bicyclerd Ltd | Bicyclic peptide ligands specific for caix |
GB201900530D0 (en) | 2019-01-15 | 2019-03-06 | Bicyclerd Ltd | Bicyclic peptide ligands specific for CD38 |
GB201900525D0 (en) | 2019-01-15 | 2019-03-06 | Bicycletx Ltd | Bicyclic peptide ligands specific for caix |
WO2020165600A1 (en) | 2019-02-14 | 2020-08-20 | Bicycletx Limited | Bicyclic peptide ligand sting conjugates and uses thereof |
US20220135614A1 (en) | 2019-03-04 | 2022-05-05 | Bicyclerd Limited | Synthesis of bicycle toxin conjugates, and intermediates thereof |
WO2020201753A1 (en) | 2019-04-02 | 2020-10-08 | Bicycletx Limited | Bicycle toxin conjugates and uses thereof |
KR20220007098A (ko) | 2019-05-09 | 2022-01-18 | 바이사이클티엑스 리미티드 | Ox40에 특이적인 이환식 펩티드 리간드 |
EP3976067A1 (en) | 2019-05-28 | 2022-04-06 | Vib Vzw | Cd8+ t-cells lacking plexins and their application in cancer treatment |
WO2020239945A1 (en) | 2019-05-28 | 2020-12-03 | Vib Vzw | Cancer treatment by targeting plexins in the immune compartment |
TW202118770A (zh) | 2019-07-30 | 2021-05-16 | 英商拜西可泰克斯有限公司 | 異質雙環肽複合物 |
US20220363713A1 (en) | 2019-08-07 | 2022-11-17 | Belyntic GmbH | A method for modification of peptides immobilized on a solid support by traceless reductively cleavable linker molecules |
CN114787197A (zh) | 2019-08-13 | 2022-07-22 | 拜斯科技术开发有限公司 | 修饰的多聚双环肽配体 |
GB201912320D0 (en) | 2019-08-28 | 2019-10-09 | Bicycletx Ltd | PBP Binding Bicyclic Peptide Ligands |
GB201914233D0 (en) | 2019-10-02 | 2019-11-13 | Bicyclerd Ltd | Phage cyclisation assay |
JP2022551607A (ja) | 2019-10-03 | 2022-12-12 | バイスクルテクス・リミテッド | ヘテロタンデム二環式ペプチド複合体 |
GB201914872D0 (en) | 2019-10-15 | 2019-11-27 | Bicycletx Ltd | Bicyclic peptide ligand drug conjugates |
MX2022006001A (es) | 2019-11-27 | 2022-10-27 | Bicycletx Ltd | Ligandos de peptidos biciclicos especificos para el receptor 2 tipo a de efrina (epha2) y usos de los mismos. |
WO2021123767A1 (en) | 2019-12-16 | 2021-06-24 | Bicycletx Limited | Bicyclic peptide ligands specific for il-17 |
GB201918557D0 (en) | 2019-12-16 | 2020-01-29 | Bicycle Tx Ltd | Bicyclic peptide ligands specific for IL-17 |
CN110907422B (zh) * | 2019-12-16 | 2021-07-06 | 吉林大学 | 基于Ti3C2的凝血酶适体传感器及其制备方法 |
GB201918558D0 (en) | 2019-12-16 | 2020-01-29 | Bicycle Tx Ltd | Bicyclic peptide ligands specific for IL-17 |
GB201918559D0 (en) | 2019-12-16 | 2020-01-29 | Bicycle Tx Ltd | Bicyclic peptide ligands specific for IL-17 |
GB202002706D0 (en) | 2020-02-26 | 2020-04-08 | Bicycletx Ltd | Pbp3 binding bicyclic peptide ligands |
GB202002705D0 (en) | 2020-02-26 | 2020-04-08 | Bicycletx Ltd | Anti-infective bicyclic peptide conjugates |
JP2023520714A (ja) | 2020-04-06 | 2023-05-18 | バイスクルテクス・リミテッド | Tslpに特異的な二環式ペプチドリガンド |
WO2021220011A1 (en) | 2020-05-01 | 2021-11-04 | Bicycletx Limited | Anti-infective bicyclic peptide conjugates |
JP2023526067A (ja) | 2020-05-15 | 2023-06-20 | バイスクルテクス・リミテッド | 抗感染性二環式ペプチドリガンド |
KR20230065231A (ko) | 2020-06-12 | 2023-05-11 | 바이사이클티엑스 리미티드 | 에리트로포이에틴-생성시키는 간세포 수용체 a2 (epha2)의 과다발현을 특징으로 하는 질환의 치료 |
CA3189761A1 (en) | 2020-08-03 | 2022-02-10 | Gemma Mudd | Peptide-based linkers |
CN111893577B (zh) * | 2020-08-06 | 2022-03-22 | 厦门大学 | 基于4-羟基-2,6-二氟-1,3,5-苯三腈构建噬菌体展示环肽库的方法 |
CN116234931A (zh) | 2020-08-17 | 2023-06-06 | 拜斯科技术开发有限公司 | 对nectin-4具有特异性的双环缀合物及其用途 |
EP4216943A1 (en) | 2020-09-24 | 2023-08-02 | Vib Vzw | Combination of p2y6 inhibitors and immune checkpoint inhibitors |
WO2022063957A1 (en) | 2020-09-24 | 2022-03-31 | Vib Vzw | Biomarker for anti-tumor therapy |
GB202016331D0 (en) | 2020-10-15 | 2020-12-02 | Bicyclerd Ltd | Bicyclic peptide ligand drug conjugates |
JP2023549229A (ja) | 2020-11-13 | 2023-11-22 | バイスクルテクス・リミテッド | トランスフェリン受容体1(TfR1)に特異的な二環式ペプチドリガンド |
EP4274838A2 (en) | 2021-01-08 | 2023-11-15 | BicycleTx Limited | Bicyclic peptide ligands specific for nk cells |
US20240083944A1 (en) | 2021-01-08 | 2024-03-14 | Bicycle TX Limited | Anti-infective bicyclic peptide ligands |
CA3206529A1 (en) | 2021-01-08 | 2022-07-14 | Bicycletx Limited | Heterotandem bicyclic peptide complexes |
WO2022148971A1 (en) | 2021-01-08 | 2022-07-14 | Bicycletx Limited | Anti-infective bicyclic peptide ligands |
EP4274839A1 (en) | 2021-01-08 | 2023-11-15 | BicycleTx Limited | Anti-infective bicyclic peptide ligands |
JP2024504068A (ja) | 2021-01-08 | 2024-01-30 | バイスクルテクス・リミテッド | 抗感染性二環式ペプチドリガンド |
CN117120459A (zh) | 2021-01-08 | 2023-11-24 | 拜斯科技术开发有限公司 | 抗感染双环肽配体 |
AU2022206395A1 (en) | 2021-01-11 | 2023-08-17 | Bicycletx Limited | Methods for treating cancer |
AU2021421391A1 (en) | 2021-01-24 | 2023-07-20 | Michael David FORREST | Inhibitors of atp synthase - cosmetic and therapeutic uses |
CA3211257A1 (en) | 2021-02-17 | 2022-08-25 | Vib Vzw | Inhibition of slc4a4 in the treatment of cancer |
JP2024509996A (ja) | 2021-03-19 | 2024-03-05 | バイスクルテクス・リミテッド | Trem2に特異的な二環式ペプチドリガンド |
WO2022199804A1 (en) | 2021-03-24 | 2022-09-29 | Vib Vzw | Nek6 inhibition to treat als and ftd |
CN117203219A (zh) | 2021-04-20 | 2023-12-08 | 拜斯科技术开发有限公司 | 特异性针对p-选择素的双环肽配体 |
CA3227511A1 (en) | 2021-08-06 | 2023-02-09 | Lætitia LINARES | Methods for the treatment of cancer |
WO2023031623A2 (en) | 2021-09-03 | 2023-03-09 | Bicycletx Limited | Synthesis of bicycle toxin conjugates, and intermediates thereof |
GB202114282D0 (en) | 2021-10-06 | 2021-11-17 | Bicyclerd Ltd | Bicyclic peptide ligand drug conjugates |
GB202114279D0 (en) | 2021-10-06 | 2021-11-17 | Bicycletx Ltd | Bicyclic peptide ligand drug conjugates |
GB202116263D0 (en) | 2021-11-11 | 2021-12-29 | Bicycletx Ltd | Anti-infective bicyclic peptide ligands |
GB202116266D0 (en) | 2021-11-11 | 2021-12-29 | Bicycletx Ltd | Novel use |
CN114166924A (zh) * | 2021-12-03 | 2022-03-11 | 中国医学科学院北京协和医院 | 尿液蛋白标志物在诊断遗传性血管水肿中的用途 |
WO2023139292A1 (en) | 2022-01-24 | 2023-07-27 | Cambridge Enterprise Limited | Tau therapy |
GB202206431D0 (en) | 2022-05-03 | 2022-06-15 | Bicycletx Ltd | Bicyclic peptide ligands specific for transferrin receptor 1 (TfR1) |
WO2024009108A1 (en) | 2022-07-07 | 2024-01-11 | Bicycletx Limited | Anti-infective bicyclic peptide ligands |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9313509D0 (en) * | 1993-06-30 | 1993-08-11 | Medical Res Council | Chemisynthetic libraries |
WO1998036743A1 (en) | 1997-02-21 | 1998-08-27 | Cypros Pharmaceutical Corporation | Neuroprotective poly-guanidino compounds which block presynaptic n and p/q calcium channels |
DE60041119D1 (de) * | 1999-07-20 | 2009-01-29 | Morphosys Ag | Verfahren zur präsentation von (poly)peptiden/proteinen auf bakteriophagenpartikeln via disulfidbindungen |
WO2001023619A1 (en) | 1999-09-29 | 2001-04-05 | Xenoport, Inc. | Compounds displayed on replicable genetic packages and methods of using same |
WO2002077182A2 (en) | 2001-03-21 | 2002-10-03 | Xenoport, Inc. | Compounds displayed on icosahedral phage and methods of using same |
US20030235851A1 (en) | 2002-04-19 | 2003-12-25 | Roberts Richard W. | Methods of using sense and/or nonsense suppression to make nucleic acid-peptide display libraries containing peptides with unnatural amino acid residues |
EP1452868A2 (en) | 2003-02-27 | 2004-09-01 | Pepscan Systems B.V. | Method for selecting a candidate drug compound |
DK1844337T3 (da) * | 2005-01-24 | 2013-09-30 | Pepscan Systems Bv | Bindingsforbindelser, immunogene forbindelser og peptidmimetika |
WO2006095345A2 (en) | 2005-03-08 | 2006-09-14 | Ramot At Tel-Aviv University Ltd. | Targeted drug-carrying bacteriophages |
WO2008013454A2 (en) * | 2006-07-26 | 2008-01-31 | Pepscan Systems B.V. | Immunogenic compounds and protein mimics |
WO2008074895A1 (en) * | 2006-12-21 | 2008-06-26 | Cytos Biotechnology Ag | Circular ccr5 peptide conjugates and uses thereof |
-
2009
- 2009-02-04 EP EP13167204.0A patent/EP2653545A1/en not_active Withdrawn
- 2009-02-04 AU AU2009211253A patent/AU2009211253B2/en active Active
- 2009-02-04 US US12/866,214 patent/US8680022B2/en active Active
- 2009-02-04 PT PT09708496T patent/PT2257624E/pt unknown
- 2009-02-04 EP EP12151953.2A patent/EP2474613B2/en active Active
- 2009-02-04 PL PL09708496T patent/PL2257624T3/pl unknown
- 2009-02-04 DK DK12151953.2T patent/DK2474613T3/da active
- 2009-02-04 JP JP2010545546A patent/JP6074574B2/ja active Active
- 2009-02-04 DK DK09708496.6T patent/DK2257624T5/da active
- 2009-02-04 AT AT09708496T patent/ATE555200T1/de active
- 2009-02-04 ES ES12151953.2T patent/ES2509959T3/es active Active
- 2009-02-04 ES ES09708496T patent/ES2383191T3/es active Active
- 2009-02-04 EP EP13167202.4A patent/EP2653543A1/en not_active Withdrawn
- 2009-02-04 EP EP09708496A patent/EP2257624B9/en active Active
- 2009-02-04 EP EP13167203.2A patent/EP2653544A1/en not_active Ceased
- 2009-02-04 CA CA2714477A patent/CA2714477C/en active Active
- 2009-02-04 WO PCT/GB2009/000301 patent/WO2009098450A2/en active Application Filing
-
2013
- 2013-08-22 US US13/973,297 patent/US9657288B2/en active Active
-
2014
- 2014-07-23 US US14/339,327 patent/US9670484B2/en active Active
-
2015
- 2015-01-23 JP JP2015011208A patent/JP6075658B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
EP2474613B1 (en) | 2014-07-16 |
EP2653544A1 (en) | 2013-10-23 |
DK2474613T3 (da) | 2014-10-06 |
EP2257624B9 (en) | 2012-08-01 |
EP2653543A1 (en) | 2013-10-23 |
PT2257624E (pt) | 2012-05-29 |
EP2474613B2 (en) | 2022-02-16 |
ATE555200T1 (de) | 2012-05-15 |
US9670484B2 (en) | 2017-06-06 |
JP2011514803A (ja) | 2011-05-12 |
ES2383191T3 (es) | 2012-06-19 |
ES2383191T9 (es) | 2012-10-16 |
WO2009098450A3 (en) | 2009-10-29 |
WO2009098450A2 (en) | 2009-08-13 |
EP2474613A1 (en) | 2012-07-11 |
DK2257624T3 (da) | 2012-05-29 |
JP6074574B2 (ja) | 2017-02-08 |
JP6075658B2 (ja) | 2017-02-08 |
DK2257624T5 (da) | 2012-09-10 |
AU2009211253A1 (en) | 2009-08-13 |
US20150166988A1 (en) | 2015-06-18 |
US20100317547A1 (en) | 2010-12-16 |
US8680022B2 (en) | 2014-03-25 |
CA2714477C (en) | 2018-10-16 |
EP2653545A1 (en) | 2013-10-23 |
JP2015109856A (ja) | 2015-06-18 |
US20140187757A1 (en) | 2014-07-03 |
PL2257624T3 (pl) | 2012-09-28 |
CA2714477A1 (en) | 2009-08-13 |
US9657288B2 (en) | 2017-05-23 |
AU2009211253B2 (en) | 2014-11-06 |
EP2257624A2 (en) | 2010-12-08 |
EP2257624B1 (en) | 2012-04-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2509959T3 (es) | Métodos y composiciones | |
Northfield et al. | Disulfide-rich macrocyclic peptides as templates in drug design | |
De Veer et al. | Cyclotides: from structure to function | |
Wang et al. | Designing macrocyclic disulfide-rich peptides for biotechnological applications | |
Baeriswyl et al. | Polycyclic peptide therapeutics | |
ES2647076T3 (es) | Peptidomiméticos de horquilla beta | |
ES2650625T3 (es) | Modulación de la especificidad de polipéptidos estructurados | |
ES2287206T3 (es) | Proceso para el desarrollo de mini-proteinas de union. | |
ES2362424T3 (es) | Biblioteca del dominio kunitz. | |
ES2242620T3 (es) | Estructuras peptidicas para exhibir bibliotecas de giros de un fago. | |
EP3107928B1 (en) | Blood brain barrier shuttle | |
Lesner et al. | Sunflower trypsin inhibitor 1 as a molecular scaffold for drug discovery | |
AU2016256226A1 (en) | Novel inhibitors of the enzyme activated factor XII (FXIIa) | |
Corbi-Verge et al. | Strategies to develop inhibitors of motif-mediated protein-protein interactions as drug leads | |
Gunasekera et al. | Making ends meet: microwave-accelerated synthesis of cyclic and disulfide rich proteins via in situ thioesterification and native chemical ligation | |
Franke et al. | Buried treasure: biosynthesis, structures and applications of cyclic peptides hidden in seed storage albumins | |
ES2453540T3 (es) | Peptidomiméticos de horquilla beta fijados a patrón con actividad inhibitoria de proteasa | |
ES2957258T3 (es) | Peptidomiméticos de horquilla beta como inhibidores selectivos de elastasa | |
Liu et al. | An ultrapotent and selective cyclic peptide inhibitor of human β-factor XIIa in a cyclotide scaffold | |
ES2552944T3 (es) | Peptidomiméticos de horquilla beta como antagonistas de CXCR4 | |
Smith et al. | Cyclotides: a patent review | |
BRPI0117190B1 (pt) | composto, composição farmacêutica, processo para a fabricação de um composto e uso do mesmo | |
Fetse et al. | Recent advances in the development of therapeutic peptides | |
JP2008533118A (ja) | ペプチド安定化化合物とスクリーニング方法 | |
Schirra et al. | Structure and folding of potato type II proteinase inhibitors: circular permutation and intramolecular domain swapping |